The early breast cancer treatment approach: “neoadjuvant” and “adjuvant” Treating breast cancer early – before it has spread – may improve the chances of preventing the disease from returning and reaching an incurable stage. Therefore, treating early breast cancer requires a comprehensive approach that may involve treatment before (“neoadjuvant”) and after (“adjuvant”) surgery. Neoadjuvant treatment aims to shrink the tumour as much as possible so that it is possible or easier to remove surgically. This may help improve surgical outcomes and conserve a patient’s breast. It may also allow a doctor to quickly assess whether a medicine is working, so that treatment can be continued or adjusted accordingly. Adjuvant treatment aims to wipe away any cancer cells that remain after surgery, reducing as much as possible the chance of the cancer coming back. To learn more, visit Subscribe to our YouTube channel now: Get in touch with us: Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally. Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. For more information and insights visit: